Stereotactic Radiation Therapy Market By Product Type (SRS Systems, SBRT Systems, Linear Accelerators, Robotic Systems); By Application (Oncology, Neurology); By Technology (LINAC-Based Systems, Robotic Radiosurgery, Gamma Knife, ZAP-X, GammaPod); By End User (Hospitals, Oncology Centers, Research Institutions, Contract Research Organizations); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Stereotactic Radiation Therapy Market: Short-Course Tumor Ablation Becomes a Core Image-Guided Oncology Workflow (Last Updated on: June-2026)

The Global Stereotactic Radiation Therapy (SRT) Market was valued at USD 1.4 billion in 2024, and a projected CAGR of 8.5%, reaching USD 2.9 billion by 2030.

 

The Stereotactic Radiation Therapy Market is transitioning from a specialized radiosurgery application toward broader adoption of short-course, image-guided cancer treatment. Stereotactic radiation therapy, including stereotactic body radiation therapy (SBRT), stereotactic ablative radiotherapy (SABR), and stereotactic radiosurgery (SRS), delivers high-dose, highly conformal radiation typically over one to five fractions, enabling treatment of selected tumors with reduced treatment visits while minimizing dose exposure to surrounding healthy tissues.

 

The market is not defined by precision alone, but by its ability to transform clinical workflows. SBRT and SRS allow cancer centers to deliver ablative local therapy in outpatient settings, reduce treatment duration, preserve radiotherapy capacity, and coordinate more easily with systemic therapy. This is why stereotactic radiation is gaining weight in early-stage non-small cell lung cancer, localized prostate cancer, brain metastases, spine metastases, liver tumors, pancreatic tumors, oligometastatic disease, and selected recurrent cancers.

 

SBRT, SABR, and SRS Move into Mainstream Oncology

Stereotactic radiation therapy is best characterized as a high-dose local tumor control approach. SBRT and SABR are mainly used outside the brain, while SRS remains central to intracranial and functional radiosurgery. The clinical mechanism is different from conventional multi-week radiotherapy because high-dose fractions can create direct tumor-cell injury, vascular damage inside the tumor microenvironment, and immune-stimulating tumor antigen release. This makes stereotactic radiation attractive not only as local therapy, but also as a platform for combination studies with immunotherapy and targeted agents.

The market is expanding as stereotactic radiotherapy aligns with contemporary oncology priorities, including reduced treatment fractions, improved organ-at-risk sparing, enhanced target delineation, and shorter overall treatment duration. In patients receiving chemotherapy, immunotherapy, targeted agents, or active surveillance, hypofractionated radiation schedules may minimize treatment disruption and improve integration within multimodal care pathways.

 

Lung, Prostate, and Brain Metastases Anchor Demand

Early-stage NSCLC represents one of the most well-established commercial applications. Lung cancer accounted for about 2.48 million new cases globally in 2022, and NSCLC represents around 80% to 85% of lung cancer cases. SBRT is especially important for medically inoperable early-stage NSCLC, where surgery may not be feasible because of age, frailty, poor lung function, or cardiac disease. This makes lung SBRT one of the most established use cases in the market. [National Cancer Institute – NSCLC Overview]

Prostate cancer is emerging as a second high-volume opportunity for stereotactic body radiotherapy. Globally, prostate cancer accounted for about 1.47 million new cases in 2022. Five-fraction SBRT is gaining clinical relevance because it can reduce treatment visits compared with conventional or moderately hypofractionated schedules. The PACE-B trial strengthened this shift by showing five-fraction SBRT as a robust alternative for appropriate localized prostate cancer patients. [ClinicalTrials.gov – PACE-B Trial]

Brain metastases remain the principal driver of the stereotactic radiosurgery market. Brain metastases affect roughly 20% of patients with cancer, and U.S. estimates range from about 98,000 to more than 200,000 cases annually depending on methodology. As systemic therapies extend survival in lung cancer, breast cancer, melanoma, renal cancer, and other solid tumors, focused intracranial control becomes more important. SRS supports this need by treating limited brain lesions while reducing reliance on whole-brain radiation in selected patients. [StatPearls – Brain Metastases Overview]

 

FDA-Cleared Platforms and Clinical Workflow Ecosystem

The market is supported by FDA-cleared stereotactic radiotherapy platforms rather than a single treatment product category. CyberKnife is used for robotic SRS and SBRT across brain, spine, lung, prostate, liver, pancreas, and other body sites where radiation therapy is indicated. Elekta’s Leksell Gamma Knife remains a dedicated cranial radiosurgery platform for brain metastases, benign brain tumors, vascular malformations, trigeminal neuralgia, and selected functional indications.

LINAC-based platforms such as Varian TrueBeam, TrueBeam STx, and Edge have expanded stereotactic access because they allow hospitals to deliver both conventional radiotherapy and high-precision SRS/SBRT from the same infrastructure. ZAP-X adds a compact cranial radiosurgery signal for brain, head, and neck lesions, while GammaPod is a breast-specific stereotactic radiotherapy platform cleared for early-stage breast cancer treatment.

Competitive differentiation is increasingly shifting beyond machine precision toward overall workflow performance. Image guidance, respiratory motion management, fiducial tracking, surface-guided radiotherapy, immobilization techniques, treatment planning, and adaptive delivery now play a central role in clinical adoption. Oncology centers increasingly require reproducible patient setup, rapid planning workflows, robust organ-at-risk protection, and comprehensive quality assurance systems capable of supporting high-dose delivery over a limited number of fractions.

 

Stereotactic Radiation Therapy Market Segment Analysis

By type, SBRT/SABR represents the fastest-growing segment as it extends stereotactic radiation applications beyond intracranial indications to lung, prostate, liver, pancreas, spine, adrenal, bone, and oligometastatic disease. SRS remains the core cranial segment, especially for brain metastases, meningiomas, vestibular schwannomas, arteriovenous malformations, trigeminal neuralgia, and recurrent intracranial tumors. Fractionated stereotactic radiotherapy remains important when tumors are close to sensitive structures and single-fraction treatment may increase toxicity risk.

By application, oncology applications remain the core demand driver, with lung cancer continuing as the anchor indication because early-stage NSCLC creates a large, evidence-backed SBRT population. Prostate cancer is becoming the most important outpatient-volume opportunity because five-fraction treatment can reduce visits while preserving disease-control expectations in selected patients. Additional oncology expansion is observed in liver, pancreatic, spine, and oligometastatic disease, where SBRT/SABR is increasingly used for high-precision local tumor control and treatment consolidation.

Neurology applications are primarily driven by brain metastases, which remain the strongest SRS indication because the clinical priority is local lesion control with lower cognitive burden compared to whole-brain radiation therapy. Beyond metastases, SRS is also used in benign and functional neurological conditions such as meningiomas, vestibular schwannomas, arteriovenous malformations, and trigeminal neuralgia, where highly focused cranial dose delivery enables effective treatment while preserving surrounding neural structures.

Spine, liver, and pancreatic tumors represent the highest-complexity treatment segment, requiring strict motion management, advanced image guidance, adherence to dose constraints, and multidisciplinary patient selection. Oligometastatic disease serves as a key expansion area, with ongoing clinical trials evaluating whether SABR-directed treatment of limited metastatic sites can delay disease progression and improve survival in carefully selected patient populations.

By technology, LINAC-based SBRT has the broadest scalability because it can be integrated into existing radiation oncology departments. Robotic radiosurgery provides strong value in motion-tracked treatment and complex targets. Gamma Knife and ZAP-X remain focused cranial platforms, while GammaPod shows how stereotactic technology can be redesigned for site-specific treatment.

 

Evidence and Pipeline Direction

The next phase of market development is being increasingly defined by disease-specific clinical evidence. In prostate cancer, PACE-B supports five-fraction SBRT as a viable alternative to longer radiation schedules in appropriate localized disease. In oligometastatic cancer, SABR-COMET reported five-year overall survival of 42.3% with SABR versus 17.7% with standard care in selected patients with controlled primary cancer and one to five metastases. [ClinicalTrials.gov – SABR-COMET]

Brain metastases are entering a more differentiated treatment paradigm. A 2025 phase III trial in patients with 5 to 20 brain metastases reported better symptom and functional outcomes with stereotactic radiation compared with hippocampal-avoidance whole-brain radiation, while survival was not significantly different. This supports the market shift toward lesion-focused intracranial treatment even in patients with more than a few metastases. 

Combination therapy represents a key direction in the SBRT pipeline. Trials are testing SBRT with immunotherapy, PARP inhibitors, ATR inhibitors, and other systemic agents to improve local control and immune-mediated effects. Spatially fractionated and lattice-based SBRT approaches are also being explored for bulky or unresectable tumors, where standard uniform-dose treatment may be constrained by organ-at-risk tolerance.

 

North America Stereotactic Radiation Therapy Market

North America remains the leading region because the U.S. has a large cancer burden, advanced radiotherapy infrastructure, strong academic trial activity, and wide availability of LINAC, robotic radiosurgery, and cranial radiosurgery systems. In 2026, the U.S. is projected to record about 229,410 lung and bronchus cancer cases and about 333,830 prostate cancer cases. Since NSCLC accounts for around 80% to 85% of lung cancer, the U.S. lung SBRT opportunity is clinically meaningful even before metastatic and recurrent indications are considered. [SEER – Prostate Cancer Statistics] [SEER – Lung Cancer Statistics]

Brain metastases also support the North American SRS base. U.S. estimates range from about 98,000 to 170,000 brain metastasis cases annually in StatPearls, while other contemporary oncology sources cite more than 200,000 cases per year. This large intracranial disease pool supports demand for Gamma Knife, CyberKnife, LINAC-based SRS, and newer cranial radiosurgery platforms. [StatPearls – Brain Metastases]

The region’s growth is not only center-based. It is workflow-based. Hospitals that can standardize image guidance, motion management, treatment planning, quality assurance, and multidisciplinary case selection will be better positioned to expand stereotactic use beyond tertiary centers. The most attractive growth areas are lung SBRT, prostate SBRT, brain metastases SRS, spine SBRT, and oligometastatic treatment.

 

Evolving Market Landscape

The Stereotactic Radiation Therapy Market is transitioning into a short-course precision oncology standard, where clinical value is increasingly defined by ablative local tumor control delivered in fewer fractions. Growth is being driven by the need to reduce treatment burden, improve organ-at-risk protection, and integrate radiation more tightly with systemic therapies in multi-modality cancer care pathways.

Competitive differentiation is shifting away from standalone hardware precision toward end-to-end workflow performance. Modern stereotactic platforms are expected to unify imaging, treatment planning, motion management, patient positioning, sub-millimeter targeting, rapid dose delivery, adaptive capabilities, and stringent quality assurance into a reproducible clinical pipeline that can operate reliably across high-throughput oncology settings.

At the same time, SRS and SBRT are moving out of niche radiosurgery suites and becoming embedded in routine radiation oncology practice. Adoption is expanding most strongly across lung cancer, prostate cancer, brain metastases, spine disease, and oligometastatic settings, where clinical evidence, shorter treatment schedules, and improved patient tolerance are collectively reshaping stereotactic radiation into a mainstream standard-of-care pathway rather than a specialized intervention.

 

Stereotactic Radiation Therapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.4 Billion
Revenue Forecast in 2030	USD 2.9 Billion
Overall Growth Rate	CAGR of 8.5% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	SRS Systems, SBRT Systems, Linear Accelerators, Robotic Systems
By Application	Oncology, Neurology
By End User	Hospitals, Oncology Centers, Research Institutions, CROs
By Technology	LINAC-Based Systems, Robotic Radiosurgery, Gamma Knife, ZAP-X, GammaPod
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., U.K., Germany, China, India, Japan, Brazil, etc.
Market Drivers	Increasing cancer burden, Technological advancements, Growth in non-invasive treatment demand
Customization Option	Available upon request